Stacey A Kenfield1, Erin L Van Blarigan2, Natalie DuPre2, Meir J Stampfer2, Edward L Giovannucci2, June M Chan2. 1. Department of Urology, University of California, San Francisco, San Francisco, CA (ELVB, SAK, JMC); Department of Epidemiology, Harvard School of Public Health, Boston, MA (SAK, ND, MJS, EG); Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA (ELVB, JMC); Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (MJS, EG); Department of Nutrition, Harvard School of Public Health, Boston, MA (MJS, EG). KenfieldS@urology.ucsf.edu. 2. Department of Urology, University of California, San Francisco, San Francisco, CA (ELVB, SAK, JMC); Department of Epidemiology, Harvard School of Public Health, Boston, MA (SAK, ND, MJS, EG); Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA (ELVB, JMC); Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (MJS, EG); Department of Nutrition, Harvard School of Public Health, Boston, MA (MJS, EG).
Abstract
BACKGROUND: Few studies have evaluated the relation between selenium supplementation after diagnosis and prostate cancer outcomes. METHODS: We prospectively followed 4459 men initially diagnosed with nonmetastatic prostate cancer in the Health Professionals Follow-Up Study from 1988 through 2010 and examined whether selenium supplement use (from selenium-specific supplements and multivitamins) after diagnosis was associated with risk of biochemical recurrence, prostate cancer mortality, and, secondarily, cardiovascular disease mortality and overall mortality, using Cox proportional hazards models. All P values were from two-sided tests. RESULTS: We documented 965 deaths, 226 (23.4%) because of prostate cancer and 267 (27.7%) because of cardiovascular disease, during a median follow-up of 8.9 years. In the biochemical recurrence analysis, we documented 762 recurrences during a median follow-up of 7.8 years. Crude rates per 1000 person-years for prostate cancer death were 5.6 among selenium nonusers and 10.5 among men who consumed 140 or more μg/day. Crude rates per 1000 person-years were 28.2 vs 23.5 for all-cause mortality and 28.4 vs 29.3 for biochemical recurrence, for nonuse vs highest-dose categories, respectively. In multivariable analyses, men who consumed 1 to 24 μg/day, 25 to 139 μg/day, and 140 or more μg/day of supplemental selenium had a 1.18 (95% confidence interval [CI] = 0.73 to 1.91), 1.33 (95% CI = 0.77 to 2.30), and 2.60-fold (95% CI = 1.44 to 4.70) greater risk of prostate cancer mortality compared with nonusers, respectively, P trend = .001. There was no statistically significant association between selenium supplement use and biochemical recurrence, cardiovascular disease mortality, or overall mortality. CONCLUSION: Selenium supplementation of 140 or more μg/day after diagnosis of nonmetastatic prostate cancer may increase risk of prostate cancer mortality. Caution is warranted regarding usage of such supplements among men with prostate cancer.
BACKGROUND: Few studies have evaluated the relation between selenium supplementation after diagnosis and prostate cancer outcomes. METHODS: We prospectively followed 4459 men initially diagnosed with nonmetastatic prostate cancer in the Health Professionals Follow-Up Study from 1988 through 2010 and examined whether selenium supplement use (from selenium-specific supplements and multivitamins) after diagnosis was associated with risk of biochemical recurrence, prostate cancer mortality, and, secondarily, cardiovascular disease mortality and overall mortality, using Cox proportional hazards models. All P values were from two-sided tests. RESULTS: We documented 965 deaths, 226 (23.4%) because of prostate cancer and 267 (27.7%) because of cardiovascular disease, during a median follow-up of 8.9 years. In the biochemical recurrence analysis, we documented 762 recurrences during a median follow-up of 7.8 years. Crude rates per 1000 person-years for prostate cancer death were 5.6 among selenium nonusers and 10.5 among men who consumed 140 or more μg/day. Crude rates per 1000 person-years were 28.2 vs 23.5 for all-cause mortality and 28.4 vs 29.3 for biochemical recurrence, for nonuse vs highest-dose categories, respectively. In multivariable analyses, men who consumed 1 to 24 μg/day, 25 to 139 μg/day, and 140 or more μg/day of supplemental selenium had a 1.18 (95% confidence interval [CI] = 0.73 to 1.91), 1.33 (95% CI = 0.77 to 2.30), and 2.60-fold (95% CI = 1.44 to 4.70) greater risk of prostate cancer mortality compared with nonusers, respectively, P trend = .001. There was no statistically significant association between selenium supplement use and biochemical recurrence, cardiovascular disease mortality, or overall mortality. CONCLUSION:Selenium supplementation of 140 or more μg/day after diagnosis of nonmetastatic prostate cancer may increase risk of prostate cancer mortality. Caution is warranted regarding usage of such supplements among men with prostate cancer.
Authors: Deborah A Kuban; Larry B Levy; Louis Potters; David C Beyer; John C Blasko; Brian J Moran; Jay P Ciezki; Anthony L Zietman; Michael J Zelefsky; Thomas M Pisansky; Mohamed Elshaikh; Eric M Horwitz Journal: Int J Radiat Oncol Biol Phys Date: 2006-06-05 Impact factor: 7.038
Authors: Emily C Chiang; Shuren Shen; Seema S Kengeri; Huiping Xu; Gerald F Combs; J Steven Morris; David G Bostwick; David J Waters Journal: Dose Response Date: 2009-12-21 Impact factor: 2.658
Authors: David J Waters; Shuren Shen; Lawrence T Glickman; Dawn M Cooley; David G Bostwick; Junqi Qian; Gerald F Combs; J Steven Morris Journal: Carcinogenesis Date: 2005-04-07 Impact factor: 4.944
Authors: K Yoshizawa; W C Willett; S J Morris; M J Stampfer; D Spiegelman; E B Rimm; E Giovannucci Journal: J Natl Cancer Inst Date: 1998-08-19 Impact factor: 13.506
Authors: Brian L Lindshield; Nikki A Ford; Kirstie Canene-Adams; Alan M Diamond; Matthew A Wallig; John W Erdman Journal: PLoS One Date: 2010-04-29 Impact factor: 3.240
Authors: M S Stratton; M E Reid; G Schwartzberg; F E Minter; B K Monroe; D S Alberts; J R Marshall; F R Ahmann Journal: Anticancer Drugs Date: 2003-09 Impact factor: 2.248
Authors: Raghu Sinha; John Thomas Pinto; Nicole Facompre; Jeff Kilheffer; John E Baatz; Karam El-Bayoumy Journal: Nutr Cancer Date: 2008 Impact factor: 2.900
Authors: Joanne M Jeter; Tawnya L Bowles; Clara Curiel-Lewandrowski; Susan M Swetter; Fabian V Filipp; Zalfa A Abdel-Malek; Larisa J Geskin; Jerry D Brewer; Jack L Arbiser; Jeffrey E Gershenwald; Emily Y Chu; John M Kirkwood; Neil F Box; Pauline Funchain; David E Fisher; Kari L Kendra; Ashfaq A Marghoob; Suephy C Chen; Michael E Ming; Mark R Albertini; John T Vetto; Kim A Margolin; Sherry L Pagoto; Jennifer L Hay; Douglas Grossman; Darrel L Ellis; Mohammed Kashani-Sabet; Aaron R Mangold; Svetomir N Markovic; Frank L Meyskens; Kelly C Nelson; Jennifer G Powers; June K Robinson; Debjani Sahni; Aleksandar Sekulic; Vernon K Sondak; Maria L Wei; Jonathan S Zager; Robert P Dellavalle; John A Thompson; Martin A Weinstock; Sancy A Leachman; Pamela B Cassidy Journal: Cancer Date: 2018-10-03 Impact factor: 6.860
Authors: Natasha Gupta; Hiten D Patel; Jacob Taylor; James F Borin; Kenneth Jacobsohn; Stacey A Kenfield; Scott E Eggener; Carrie Price; Meena Davuluri; Nataliya Byrne; Trinity J Bivalacqua; Stacy Loeb Journal: Prostate Cancer Prostatic Dis Date: 2022-07-05 Impact factor: 5.455
Authors: Vicente Javier Clemente-Suárez; Laura Redondo-Flórez; Alejandro Rubio-Zarapuz; Ismael Martínez-Guardado; Eduardo Navarro-Jiménez; José Francisco Tornero-Aguilera Journal: Int J Environ Res Public Health Date: 2022-04-11 Impact factor: 4.614
Authors: Philip W Kantoff; Lorelei A Mucci; June M Chan; Amy K Darke; Kathryn L Penney; Catherine M Tangen; Phyllis J Goodman; Gwo-Shu Mary Lee; Tong Sun; Sam Peisch; Alex M Tinianow; James M Rae; Eric A Klein; Ian M Thompson Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-05-06 Impact factor: 4.254
Authors: Wanling Xie; Ming Yang; June Chan; Tong Sun; Lorelei A Mucci; Kathryn L Penney; Gwo-Shu Mary Lee; Philip W Kantoff Journal: Prostate Date: 2016-02-05 Impact factor: 4.104
Authors: Sam F Peisch; Erin L Van Blarigan; June M Chan; Meir J Stampfer; Stacey A Kenfield Journal: World J Urol Date: 2016-08-12 Impact factor: 4.226
Authors: Naomi E Allen; Ruth C Travis; Paul N Appleby; Demetrius Albanes; Matt J Barnett; Amanda Black; H Bas Bueno-de-Mesquita; Mélanie Deschasaux; Pilar Galan; Gary E Goodman; Phyllis J Goodman; Marc J Gunter; Markku Heliövaara; Kathy J Helzlsouer; Brian E Henderson; Serge Hercberg; Paul Knekt; Laurence N Kolonel; Christina Lasheras; Jakob Linseisen; E Jeffrey Metter; Marian L Neuhouser; Anja Olsen; Valeria Pala; Elizabeth A Platz; Harri Rissanen; Mary E Reid; Jeannette M Schenk; Meir J Stampfer; Pär Stattin; Catherine M Tangen; Mathilde Touvier; Antonia Trichopoulou; Piet A van den Brandt; Timothy J Key Journal: J Natl Cancer Inst Date: 2016-07-06 Impact factor: 13.506
Authors: Jakub Lubiński; Wojciech Marciniak; Magdalena Muszynska; Ewa Jaworowska; Mieczyslaw Sulikowski; Anna Jakubowska; Katarzyna Kaczmarek; Grzegorz Sukiennicki; Michal Falco; Piotr Baszuk; Magdalena Mojsiewicz; Joanne Kotsopoulos; Ping Sun; Steven A Narod; Jan A Lubiński Journal: PLoS One Date: 2018-01-05 Impact factor: 3.240